Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Update from the latest WHO classification of MPNs: a user's manual.

Hematology. American Society of Hematology. Education Program - 2 Dec 2016

Passamonti Francesco, Maffioli Margherita

Abstract excerpt

The 2016 multiparameter World Health Organization (WHO) classification for Philadelphia-negative myeloproliferative neoplasms (MPNs) integrates clinical features, morphology, and genetic data to diagnose polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The main novelties are: (1) the reduction of the hemoglobin (Hb) level threshold to diagnose PV, now established at 16.5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CALR gene
Share to MPL gene
Share to SRSF2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematologic Neoplasms

Share to Mutation

Share to Myeloproliferative Disorders

Share to Neoplasm Proteins

Share to World Health Organization

Source

Open in PubMed Open full text

Identifiers

PMID: 27913526
DOI: 10.1182/asheducation-2016.1.534
PMCID: PMC6142477

Genes

ASXL1
CALR
IDH1
IDH2
JAK2
MPL
SRSF2
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Update from the latest WHO classification of MPNs: a user's manual.PMID 27913526Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.Semantic proximity Read ↗

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.Semantic proximity Read ↗

[CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?]Semantic proximity Read ↗

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemiaSemantic proximity Read ↗

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.Semantic proximity Read ↗

[Myeloproliferative neoplasms: revisions in the 2016 WHO criteria].Semantic proximity Read ↗

The 2008 World Health Organization classification system for myeloproliferative neoplasmsSemantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm VariantsSemantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Guidelines for the management of myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.